| 1 |
Tsuji A, Ikeda Y, Yoshikawa S, Taniguchi K, Sawamura H, Morikawa S, Nakashima M, Asai T, Matsuda S. The Tryptophan and Kynurenine Pathway Involved in the Development of Immune-Related Diseases. IJMS 2023;24:5742. [DOI: 10.3390/ijms24065742] [Reference Citation Analysis]
|
| 2 |
Yoshikawa S, Taniguchi K, Sawamura H, Ikeda Y, Tsuji A, Matsuda S. A New Concept of Associations between Gut Microbiota, Immunity and Central Nervous System for the Innovative Treatment of Neurodegenerative Disorders. Metabolites 2022;12:1052. [DOI: 10.3390/metabo12111052] [Reference Citation Analysis]
|
| 3 |
Shavkuta G, Federal State Budgetary Educational Institution of Higher Education ", Yakovleva N, Shnyukova T, Rostov State Medical University", of the Ministry of Health of Russia, Federal State Budgetary Educational Institution of Higher Education "Rostov State Medical University" of the Ministry of Health of Russia, Federal State Budgetary Educational Institution of Higher Education "Rostov State Medical University" of the Ministry of Health of Russia. Role of gut microbiota in the pathogenesis of neurodegenerative diseases. General Physician 2022. [DOI: 10.33920/med-12-2209-07] [Reference Citation Analysis]
|
| 4 |
Sawamura H, Taniguchi K, Ikeda Y, Tsuji A, Kitagishi Y, Matsuda S. Gut microbiota could modulate the effects of neuro-immune responses and memory traces via the gut-brain-immune axis in schizophrenia. Explor Neuroprot Ther 2022. [DOI: 10.37349/ent.2022.00019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 5 |
Taniguchi K, Sawamura H, Ikeda Y, Tsuji A, Kitagishi Y, Matsuda S. D-Amino Acids as a Biomarker in Schizophrenia. Diseases 2022;10:9. [DOI: 10.3390/diseases10010009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 6 |
Yoshikawa S, Taniguchi K, Sawamura H, Ikeda Y, Tsuji A, Matsuda S. Encouraging probiotics for the prevention and treatment of immune-related adverse events in novel immunotherapies against malignant glioma. Explor Target Antitumor Ther 2022;3:817-27. [PMID: 36654824 DOI: 10.37349/etat.2022.00114] [Reference Citation Analysis]
|
